BridgeBio Pharma, Inc.
BBIO
$61.37
-$0.61-0.98%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 4,318.01% | 4,999.86% | -44.76% | 237.08% | -33.22% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4,318.01% | 4,999.86% | -44.76% | 237.08% | -33.22% |
| Cost of Revenue | 997.49% | 510.87% | 341.30% | 248.49% | 0.00% |
| Gross Profit | 5,248.50% | 6,709.68% | -45.85% | 231.12% | -38.91% |
| SG&A Expenses | 99.98% | 116.98% | 61.63% | 99.19% | 92.36% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 35.39% | 39.60% | 6.30% | 27.36% | 17.55% |
| Operating Income | 27.13% | 22.69% | -2,873.23% | -25.29% | -18.87% |
| Income Before Tax | -13.53% | -140.47% | -369.05% | -56.31% | 8.49% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -12.59% | -143.25% | -369.05% | -56.98% | 8.49% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -0.90% | -11.16% | 131.57% | 7.29% | -11.05% |
| Net Income | -12.78% | -147.64% | -375.41% | -57.63% | 8.45% |
| EBIT | 27.13% | 22.69% | -2,873.23% | -25.29% | -18.87% |
| EBITDA | 27.28% | 22.75% | -2,020.17% | -25.64% | -19.14% |
| EPS Basic | -10.81% | -143.82% | -346.73% | -45.16% | 20.69% |
| Normalized Basic EPS | 17.78% | 10.45% | -959.38% | -26.71% | -6.12% |
| EPS Diluted | -10.81% | -143.82% | -346.73% | -45.16% | 20.69% |
| Normalized Diluted EPS | 17.78% | 10.45% | -959.38% | -26.71% | -6.12% |
| Average Basic Shares Outstanding | 1.77% | 1.56% | 6.40% | 8.58% | 15.43% |
| Average Diluted Shares Outstanding | 1.77% | 1.56% | 6.40% | 8.58% | 15.43% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |